public assessment report ukpar ibuprofen 200 mg/ 5ml oral ... · par ibuprofen 200 mg/ 5ml oral...
TRANSCRIPT
Public Assessment Report
UKPAR
Ibuprofen 200 mg/ 5ml oral suspension
(Ibuprofen)
UK Licence No: PL 35533/0056
Aspire Pharma Limited.
PAR Ibuprofen 200 mg/ 5ml oral suspension PL 35533/0056
2
LAY SUMMARY
Ibuprofen 200 mg/ 5ml oral suspension
This is a summary of the Public Assessment Report (PAR) for Ibuprofen 200 mg/ 5ml oral suspension
(PL 35533/0056). It explains how Ibuprofen 200 mg/ 5ml oral suspension was assessed and its
authorisation recommended, as well as it’s conditions of use. It is not intended to provide practical
advice on how to use Ibuprofen 200 mg/ 5ml oral suspension.
The product will be collectively referred to as Ibuprofen oral suspension throughout the remainder of
this public assessment report.
For practical information about using Ibuprofen oral suspension, patients should read the package leaflet
or contact their doctor or pharmacist.
What is Ibuprofen oral suspension and what is it used for?
This medicine is the same as Ibuprofen 200 mg/5ml oral suspension (Aspire Pharma Limited), which is
already authorised. The company (Aspire Limited) that makes Ibuprofen 200 mg/5ml oral suspension
(PL 35533/0034) has agreed that its scientific data can be used as a basis for the grant of identical
licence for Ibuprofen oral suspension (PL 35533/0056).
Ibuprofen oral suspension is for use in children from 10 kg body weight (1 year of age), adolescents and
adults.
This medicine is used in the short-term treatment of:
• mild to moderate pain such as dental pain, headache.
• fever.
How does Ibuprofen oral suspension work?
Ibuprofen oral suspension contains the active ingredient ibuprofen which belongs to a group of
medicines called non-steroidal anti-inflammatory drugs (NSAID). This medicine reduces pain and fever.
How is Ibuprofen oral suspension used?
The pharmaceutical form of this medicine is an oral suspension and the route of administration is oral
(by mouth). This medicine can be taken without the need for a meal, but if the patient has a sensitive
stomach the medicine should be taken with a meal. The bottle should be shaken vigorously before use.
The patient should always take this medicine exactly as their doctor has told them. The patient should
check with their doctor or pharmacist if they are not sure.
This medicine is for short-term use only.
PAR Ibuprofen 200 mg/ 5ml oral suspension PL 35533/0056
3
The recommended dose is:
In children and adolescents Ibuprofen oral suspension is dosed depending on body weight (BW), as a
rule with 7 to 10 mg/kg BW as a single dose to a, maximum of 30 mg/kg BW as the total daily dose. The
interval between the doses should be at least 6 hours and the recommended dose should not be exceeded.
This medicine is not recommended for use in children under 1 year of age or under 10 kg body weight.
A doctor should be consulted if the child’s symptoms worsen or persist for more than 3 days.
Consult a doctor if an adolescent and or adult’s symptoms worsen, and this medicine is required to be
taken for more than 3 days in case of a fever, or more than 4 days for the treatment of pain.
Please read section 3 of the package leaflet for detailed information on dosing recommendations, the
route of administration, and the duration of treatment.
This medicine can only be obtained with a prescription.
For further information on how Ibuprofen oral suspension is used, refer to the package leaflet and
Summary of Product Characteristics (SmPC) available on the Medicines and Healthcare products
Regulatory Agency (MHRA) website.
What benefits of Ibuprofen oral suspension have been shown in studies?
Ibuprofen oral suspension is considered identical to previously authorised Ibuprofen 200 mg/5ml oral
PAR Ibuprofen 200 mg/ 5ml oral suspension PL 35533/0056
4
suspension (PL 35533/0034), with the same benefits and risks. So, no new studies have been provided
for Ibuprofen oral suspension, but reference is made to the studies for Ibuprofen 200 mg/5ml oral
suspension (PL 35533/0034).
What are the possible side effects from Ibuprofen oral suspension?
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Ibuprofen oral suspension is considered to be identical to the previously authorised application for
Ibuprofen 200 mg/5ml oral suspension (PL 35533/0034) with the same benefits and risks.
For a full list of all the side effects reported with Ibuprofen oral suspension see section 4 of the package
leaflet, available on the Medicines and Healthcare products Regulatory Agency (MHRA) website.
For the full list of restrictions, see the package leaflet.
Why was Ibuprofen oral suspension approved?
The MHRA decided that the benefits of Ibuprofen oral suspension are greater than the risks and
recommended that it is approved for use.
What measures are being taken to ensure the safe and effective use of Ibuprofen oral suspension?
A Risk Management Plan has been developed to ensure that Ibuprofen oral suspension is used as safely
as possible. Based on this plan, safety information has been included in the Summary of Product
Characteristics and the package leaflet for Ibuprofen oral suspension including the appropriate
precautions to be followed by healthcare professionals and patients.
Known side effects are continuously monitored. Furthermore new safety signals reported by
patients/healthcare professionals will be monitored/reviewed continuously.
Other information about Ibuprofen oral suspension
Marketing Authorisation was granted in the UK on 21 December 2017.
The full PAR for Ibuprofen oral suspension follows this summary.
For more information about treatment with Ibuprofen oral suspension read the package leaflet, or contact
your doctor or pharmacist.
This summary was last updated in February 2018.
PAR Ibuprofen 200 mg/ 5ml oral suspension PL 35533/0056
5
TABLE OF CONTENTS
I Introduction Page 6
II Quality aspects Page 7
III Non-clinical aspects Page 8
IV Clinical aspects Page 8
V User consultation Page 9
VI Overall conclusion, benefit/risk assessment and
recommendation
Page 9
Table of content of the PAR update Page 13
PAR Ibuprofen 200 mg/ 5ml oral suspension PL 35533/0056
6
I INTRODUCTION
The Medicines and Healthcare products Regulatory Agency (MHRA) granted Aspire Pharma Limited
Marketing Authorisation for the medicinal product Ibuprofen 200 mg/ 5ml oral suspension (PL
35533/0056) on 21 December 2017. The product is a prescription only medicines (POM) used in the
short-term symptomatic treatment of:
• mild to moderate pain such as dental pain, headache.
• fever.
Ibuprofen oral suspension is for use in children from 10 kg body weight (1 year of age), adolescents and
adults.
This application was submitted as simple abridged (informed consent) application according to Article
10c of Directive 2001/83/EC, as amended.
The application cross-refers to the reference product Ibuprofen 200 mg/5ml oral suspension (PL
35533/0034), which was originally granted in the UK on 10 December 2014 to the marketing
authorisation holder (MAH) Aspire Pharma Limited, following a mutual recognition procedure
(DE/H/3978/001/MR) where the UK was a CMS. Subsequently the UK took over as RMS for this
procedure (UK/H/6039/01/MR) on 27 January 2015.
Ibuprofen oral suspension is a non-steroidal anti-inflammatory drug, which has been shown to be
effective through inhibition of prostaglandin synthesis in the usual animal models of inflammation. In
humans, ibuprofen reduces inflammation induced pain, swelling and fever. Furthermore, ibuprofen
reversibly inhibits ADP and collagen induced platelet aggregation.
Experimental data suggest that ibuprofen may inhibit the effect of low dose acetylsalicylic acid on
platelet aggregation when they are dosed concomitantly. In one study, when a single dose of ibuprofen
400mg was taken within 8 hours before or within 30 minutes after immediate release acetylsalicylic acid
dosing (81mg), a decreased effect of acetylsalicylic acid on the formation of thromboxane or platelet
aggregation occurred. However, the limitations of these data and the uncertainties regarding
extrapolation of ex vivo data to the clinical situation imply that no firm conclusions can be made for
regular ibuprofen use, and no clinically relevant effect is considered to be likely for occasional ibuprofen
use.
No new data were submitted nor were necessary to be submitted for these applications, as the data are
identical to the data for the previously granted reference product.
PAR Ibuprofen 200 mg/ 5ml oral suspension PL 35533/0056
7
II QUALITY ASPECTS
II.1 Introduction
This is an abridged application for Ibuprofen oral suspension (PL 35533/0056) submitted under Article
10c of Directive 2001/83/EC, as amended.
The application cross-refers to the reference product Ibuprofen 200 mg/5ml oral suspension (PL
35533/0034), which was granted in the UK on 10 December 2014 to the marketing authorisation holder
(MAH) Aspire Pharma Limited.
II.2. Drug Substance
Drug substance specifications
The proposed drug substance specifications are consistent with the details registered for the cross-
reference product.
II.3. Medicinal Product
Name
The proposed product name for this application is Ibuprofen oral suspension 200 mg/ 5ml oral
suspension. The product has been named in line with current requirements.
Strength, pharmaceutical form, route of administration, container and pack sizes
Ibuprofen oral suspension is available in amber coloured polyethylene terephthalate (PET) bottles of 30
ml, 100 ml, 150 ml and 200 ml with a child-resistant closure, which is fitted with a low-density
polyethylene (LDPE) stopper. The product is supplied with a 5 ml oral syringe, comprising a high-
density polyethylene (HDPE) piston and a polypropylene barrel. The oral syringe is graduated in 0.25 ml
steps up to 5 ml. Not all pack-sizes may be marketed.
The proposed shelf life of the unopened product is 3 years with no special storage conditions.
The in-use shelf life of the product is 6 months after first opening the bottle.
The proposed packaging, shelf-life and storage conditions are consistent with the details registered for
the reference product.
Legal status
Prescription only medicine (POM).
Marketing Authorisation Holder/Contact Persons/Company
Aspire Pharma Limited, Unit 4 Rotherbrook Court, Bedford Road, Petersfield, Hampshire, GU32 3QG,
Unite Kingdom
Manufacturers
The proposed manufacturing sites are consistent with those registered for the reference product and
evidence of Good Manufacturing Practice (GMP) compliance has been provided.
Qualitative and quantitative compositions
The proposed compositions are consistent with the details registered for the reference product.
Manufacturing process
The proposed manufacturing processes are consistent with the details registered for the reference
product and the maximum batch size is stated.
PAR Ibuprofen 200 mg/ 5ml oral suspension PL 35533/0056
8
Finished product/shelf-life specifications
The proposed finished product specifications are in line with the details registered for the reference
product.
TSE Compliance
None of the excipients used contain material of animal or human origin.
This product does not contain or consist of genetically modified organisms (GMO).
Bioequivalence
No bioequivalence data are required to support this simple abridged application because the proposed
product is manufactured to the same formulae utilising the same processes as the reference product,
Ibuprofen 200 mg/5 ml oral suspension (PL 35533/0034).
Expert Report
The applicant cross-refers to the data for Ibuprofen 200 mg/5ml oral suspension (PL 35533/0034), to
which this application is claimed to be identical. This is acceptable.
Product Name and Appearance
See Section II.3 ‘Medicinal Product; Name’ for details of the proposed product name. The appearance of
the product is identical to that of the reference product.
II.4 Discussion on chemical, pharmaceutical and biological aspects
The data submitted with the application is acceptable. The grant of Marketing Authorisation is
recommended.
III NON-CLINICAL ASPECTS
Introduction
As this application is submitted under Article 10c of Directive 2001/83/EC, as amended, (Informed
Consent Applications) no new non-clinical data have been supplied and none are required.
Ecotoxicity/environmental risk assessment (ERA)
Suitable justification has been provided for non-submission of an Environmental Risk Assessment. As
the application is an identical version of already authorised product, it is not expected that environmental
exposure will increase following approval of the Marketing Authorisation for the proposed product.
Discussion on the non-clinical aspects
The grant of Marketing Authorisation is recommended.
IV CLINICAL ASPECTS
Introduction
As this application is submitted under Article 10c of Directive 2001/83/EC, as amended, (Informed
Consent Applications) no new clinical data have been supplied and none are required.
Risk Management Plan (RMP)
The marketing authorisation holder (MAH) has submitted a risk management plan (RMP), in accordance
with the requirements of Directive 2001/83/EC as amended, describing the pharmacovigilance activities
and interventions designed to identify, characterise, prevent or minimise risks relating to Ibuprofen oral
suspension.
PAR Ibuprofen 200 mg/ 5ml oral suspension PL 35533/0056
9
The Qualified Person (QP) responsible for pharmacovigilance is stated and a satisfactory CV has been
provided.
A summary of safety concerns and planned risk minimisation activities, as approved in the RMP, are
listed below:
Summary table of safety concerns:
Routine pharmacovigilance and routine risk minimisation are proposed for all safety concerns.
Discussion on the clinical aspects
The grant of Marketing Authorisation is recommended.
V User consultation
The package leaflet has been evaluated via a user consultation study in accordance with the requirements
of Articles 59(3) and 61(1) of Directive 2001/83/EC. The language used for the purpose of user testing
the PIL was English
The results show that the package leaflet meets the criteria for readability as set out in the Guideline on
the readability of the label and package leaflet of medicinal products for human use.
VI Overall conclusion, benefit/risk assessment and recommendation
The quality of the product is acceptable, and no new non-clinical or clinical safety concerns have been
identified. The applicant’s product is identical to the reference product. Extensive clinical experience
with ibuprofen is considered to have demonstrated the therapeutic value of the compound. The
benefit/risk balance is, therefore, considered to be similar to the referenced product and positive.
PAR Ibuprofen 200 mg/ 5ml oral suspension PL 35533/0056
10
Summaries of Product Characteristics (SmPC), Patient Information Leaflets (PIL) and Labels
The SmPC and PIL are consistent with the details registered for the reference product.
In accordance with Directive 2010/84/EU the Summaries of Product Characteristics (SmPCs) and
Patient Information Leaflets (PILs) for products granted Marketing Authorisations at a national level are
available on the MHRA website.
The approved labelling for this medicine is presented below:
PAR Ibuprofen 200 mg/ 5ml oral suspension PL 35533/0056
11
PAR Ibuprofen 200 mg/ 5ml oral suspension PL 35533/0056
12
PAR Ibuprofen 200 mg/ 5ml oral suspension PL 35533/0056
13
Annex 1
Table of content of the PAR update
Steps taken after the initial procedure with an influence on the Public Assessment Report (Type II
variations, PSURs, commitments)
Scope Procedure
number
Product
information
affected
Date of
start of the
procedure
Date of end
of
procedure
Approval/
non
approval
Assessment
report
attached
Y/N
(version)